BACKGROUND The aim of this study was to compare nutrition-related adverse events and clinical outcomes of
ifosfamide,
carboplatin, and
etoposide regimen (
ICE therapy) and
ranimustine,
carboplatin,
etoposide, and
cyclophosphamide regimen (MCEC
therapy) instituted as pretreatment for autologous
peripheral blood stem cell transplantation. MATERIAL AND METHODS We enrolled patients who underwent autologous
peripheral blood stem cell transplantation between 2007 and 2012. Outcomes were compared between
ICE therapy (n=14) and MCEC
therapy (n=14) in relation to nutrient balance, engraftment day, and length of
hospital stay. In both groups, we compared the timing of nutrition-related adverse events with oral caloric intake, analyzed the correlation between length of
hospital stay and duration of
parenteral nutrition, and investigated the association between oral caloric intake and the proportion of
parenteral nutrition energy in total calorie supply. Five-year survival was compared between the groups. RESULTS Compared with the MCEC group, the
ICE group showed significant improvement in oral caloric intake, length of
hospital stay, and timing of nutrition-related adverse events and oral calorie intake, but a delay in engraftment. Both groups showed a correlation between duration of
parenteral nutrition and length of
hospital stay (P=0.0001) and between oral caloric intake (P=0.0017) and
parenteral nutrition energy sufficiency rate (r=-0.73, P=0.003; r=-0.76, P=0.002). Five-year survival was not significantly different between the groups (P=0.1355). CONCLUSIONS Our findings suggest that compared with MCEC
therapy,
ICE therapy improves nutrition-related adverse events and reduces
hospital stay, conserving medical resources, with no significant improvement in long-term survival. The nutritional pathway may serve as a tool for objective evaluation of pretreatment for autologous
peripheral blood stem cell transplantation.